Immunotherapy of Hepatocellular Carcinoma
Kurzinformation
inkl. MwSt. Versandinformationen
Artikel zZt. nicht lieferbar
Artikel zZt. nicht lieferbar

Beschreibung
In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer.Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. von Greten, Tim
Produktdetails
So garantieren wir Dir zu jeder Zeit Premiumqualität.
Über den Autor
Professor Tim F. Greten has received his training in Gastroenterology, Hepatology and Medical Oncology. He has been treating patients with hepatocellular carcinoma (HCC) for many years has been leading a number of clinical trials. Apart from his clinical expertise Professor Greten has been interested in the immunological aspects of HCC for more than 20 years. He is conducting basic research studies, which he published in the very top scientific journals including Nature, and Cancer Cell and is also a pioneer in immunotherapy studies in HCC. He published a number of different clinical trials testing different immune based approaches in HCC. Based on this medical and basic science background is considered on the world leaders in tumor immunology and immunotherapy of HCC.
- hardcover
- 576 Seiten
- Erschienen 2010
- Wiley-Blackwell
- hardcover
- 316 Seiten
- Erschienen 2015
- Elsevier
- hardcover
- 424 Seiten
- Erschienen 2008
- Wiley
- Kartoniert
- 360 Seiten
- Erschienen 2019
- Springer
- hardcover -
- Erschienen 1993
- Chapman & Hall
- hardcover
- 1822 Seiten
- Erschienen 2011
- Wiley-VCH
- hardcover
- 600 Seiten
- Erschienen 1994
- Mosby
- hardcover
- 256 Seiten
- Zuckschwerdt
- Gebunden
- 596 Seiten
- Erschienen 2009
- Springer
- Gebunden
- 482 Seiten
- Erschienen 2007
- Humana
- paperback
- 116 Seiten
- Erschienen 2022
- CRC Press




